Pular para o conteúdo principal
Ranking Invest

BCRX - BioCryst Pharmaceuticals, Inc.

Segmento: HealthcareBioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Análise Ranking Invest

Valor de Mercado
$ 2.14 Bi
IVR
-0.57Índice proprietário de comparação relativa: -0,57.
IVR2
-0.35Leitura proprietária complementar: -35%.
MLL
-0.35Leitura proprietária complementar: -35%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

-$ 454.29 Mi

Dívida Líquida

$ 240.43 Mi

L4T

-$ 384.67 Mi

MM4T

-89.25%

Indicadores Básicos

ROE

84.68%

Índices de Previsibilidade

Receita Líquida

D0.10

Lucro

D1.00

Margem

C0.51

Índices de Tendência

Receita Líquida

A11.88

Lucro

A9.16

Margem

A11.64

Índices de Endividamento

DIV/PAT

-0.53

DIV/L4T

-0.63

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.